Anistreplase (Anisoylated Plasminogen Streptokinase Activator Complex, Apsac) in Coronary Thrombolysis

  • David P. de Bono
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 193)


Anistreplase was introduced and developed as a thrombolytic agent for two reasons: first, the hope that it would act as a fibrin-selective agent and reduce the risks of hemorrhage associated with streptokinase; second, its pharmacokinetic properties, which allow it to be given as a single injection rather than an infusion. The first aspiration has not been fulfilled. The second property has, however, been very useful, particularly for prehospital fibrinolysis.


Acute Myocardial Infarction ANISOYLATED Plasminogen Streptokinase Activator Complex Acute Myocar Intracoronary Streptokinase Coronary Thrombolysis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Smith RAG, Dupe RJ, English PD, Green J. Thrombolysis with acyl enzymes: A new approach to thrombolytic therapy. Nature (Lond) 290:505, 1981.CrossRefGoogle Scholar
  2. 2.
    Been M, de Bono DP, Muir AL, Boulton FE, Hillis WS, Hornung R. Coronary thrombolysis with intravenous anisoylated plasminogen streptokinase activator complex BRL 26921. Br Heart J 53:253, 1985.PubMedCrossRefGoogle Scholar
  3. 3.
    Been M, de Bono DP, Muir AL, Boulton FE, Fears R, Standring R, Ferres H. Clinical effects and pharmaco-kinetics of intravenous APSAC (anisoylated plasminogen streptokinase activator complex, BRL26921) in acute myocardial infarction. Int J Cardiol 11:53, 1986.PubMedCrossRefGoogle Scholar
  4. 4.
    Anderson JL, Rothbard RL, Hackworthy RA, et al. Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction. Controlled comparison with intracoronary streptokinase. J Am Coll Cardiol 11:1153, 1988.PubMedGoogle Scholar
  5. 5.
    Bonnier HJRM, Visser RF, Klomps HC, Hoffman HJML, and the Dutch Invasive Reperfusion Study Group. Comparison of intravenous anisoylated plasminogen streptokinase activator complex and intra-coronary streptokinase in acute myocardial infarction. Am J Cardiol 2:25, 1988.CrossRefGoogle Scholar
  6. 6.
    Hogg KJ, Gemmill JD, Burns JMA, et al. Angiographic patency study of anistreplase versus streptokinase in acute myocardial infarction. Lancet 335:254, 1990.PubMedCrossRefGoogle Scholar
  7. 7.
    AIMS Trial Study Group. Effects of intravenous APSAC on mortality after acute myocardial infarction. Preliminary report of a placebo-controlled clinical trial. Lancet 2:545, 1988.Google Scholar
  8. 8.
    AIMS Trial Study Group. Long term effects of intravenous anistreplase in acute myocardial infarction. Final report of the AIMS study. Lancet 2:427, 1990.CrossRefGoogle Scholar
  9. 9.
    ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 39:753, 1992.Google Scholar
  10. 10.
    The European Myocardial Infarction Project Group. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 329:383, 1993.CrossRefGoogle Scholar
  11. 11.
    GREAT Group. Feasibility, safety and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. Br Med J 305:548, 1992.CrossRefGoogle Scholar
  12. 12.
    Rawles J, on behalf of the GREAT group. Halving of mortality at one year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT), J Am Coll Cardiol 23:1, 1994.PubMedCrossRefGoogle Scholar
  13. 13.
    Cannon CP, McCabe CH, Diver DJ, et al. Comparison of front-loaded tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy in acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 4 trial. J Am Coll Cardiol 24:1602, 1994.PubMedGoogle Scholar
  14. 14.
    Neuhaus KL, von Essen R, Tebbe U, et al. Improved thrombolysis in acute myocardial infarction with front loaded administration of alteplase: Result of the rt-PA-APSAC patency study (TAPS). J Am Coll Cardiol 19:885, 1992.PubMedGoogle Scholar
  15. 15.
    O’Connor CM, Meese R, Carney R, et al. A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streprokinase activator complex) in acute myocardial infarction: The Duke University Clinical Cardiology Study (DUCCS) 1. J Am Coll Cardiol 23:11, 1994.PubMedGoogle Scholar
  16. 16.
    Julian DG. Aspirin or anticoagulants after thrombolysis with anistreplase: Preliminary data from the AFTER study. Eur Heart J 13 (Abstract Suppl.): 307, 1992.Google Scholar
  17. 17.
    Vanderscheuren S, Barrios L, Kerdsinchai P, Van der Heuvel P, Hermans L, Vrolix M, et al. A randomised trial of recombinant staphylokinase versus alteplase for coronary artery patency in myocardial infarction. Circulation 92:2044, 1995.Google Scholar
  18. 18.
    Collen D. Fibrin selective thrombolytic therapy for myocardial infarction. Circulation 93:857, 1996.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • David P. de Bono

There are no affiliations available

Personalised recommendations